P10275

PTMD Annotation Information


※ Protein Information

Tag Content
UniProt Accession ANDR_HUMAN; P10275;
Entrez ID 367
GenBank Protein ID NM_000044.4; NM_001011645.3; NM_001348061.1; NM_001348063.1; NM_001348064.1;
GenBank Nucleotide ID NP_000035.2; NP_001011645.1; NP_001334990.1; NP_001334992.1; NP_001334993.1;
Protein Name Androgen receptor (Dihydrotestosterone receptor) (Nuclear receptor subfamily 3 group C member 4)
Gene Name AR; DHTR; NR3C4
Organism Homo sapiens
NCBI Taxa ID 9606
Functional DescriptionSteroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.;Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
Sequence
(Fasta)
MEVQLGLGRV YPRPPSKTYR GAFQNLFQSV REVIQNPGPR HPEAASAAPP GASLLLLQQQ 60
QQQQQQQQQQ QQQQQQQQQQ ETSPRQQQQQ QGEDGSPQAH RRGPTGYLVL DEEQQPSQPQ 120
SALECHPERG CVPEPGAAVA ASKGLPQQLP APPDEDDSAA PSTLSLLGPT FPGLSSCSAD 180
LKDILSEAST MQLLQQQQQE AVSEGSSSGR AREASGAPTS SKDNYLGGTS TISDNAKELC 240
KAVSVSMGLG VEALEHLSPG EQLRGDCMYA PLLGVPPAVR PTPCAPLAEC KGSLLDDSAG 300
KSTEDTAEYS PFKGGYTKGL EGESLGCSGS AAAGSSGTLE LPSTLSLYKS GALDEAAAYQ 360
SRDYYNFPLA LAGPPPPPPP PHPHARIKLE NPLDYGSAWA AAAAQCRYGD LASLHGAGAA 420
GPGSGSPSAA ASSSWHTLFT AEEGQLYGPC GGGGGGGGGG GGGGGGGGGG GGGEAGAVAP 480
YGYTRPPQGL AGQESDFTAP DVWYPGGMVS RVPYPSPTCV KSEMGPWMDS YSGPYGDMRL 540
ETARDHVLPI DYYFPPQKTC LICGDEASGC HYGALTCGSC KVFFKRAAEG KQKYLCASRN 600
DCTIDKFRRK NCPSCRLRKC YEAGMTLGAR KLKKLGNLKL QEEGEASSTT SPTEETTQKL 660
TVSHIEGYEC QPIFLNVLEA IEPGVVCAGH DNNQPDSFAA LLSSLNELGE RQLVHVVKWA 720
KALPGFRNLH VDDQMAVIQY SWMGLMVFAM GWRSFTNVNS RMLYFAPDLV FNEYRMHKSR 780
MYSQCVRMRH LSQEFGWLQI TPQEFLCMKA LLLFSIIPVD GLKNQKFFDE LRMNYIKELD 840
RIIACKRKNP TSCSRRFYQL TKLLDSVQPI ARELHQFTFD LLIKSHMVSV DFPEMMAEII 900
SVQVPKILSG KVKPIYFHTQ 921

※ PTM-Disease Association

NumPTMDiseaseCell TypeTypePTM SitePMID
1Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUS1612015328
[Reference]: Treatment of LNCaP cells with the synthetic androgen, R1881, elevates phosphorylation of serines 16, 81, 256, 308, 424, and 650. Ser-94 appears constitutively phosphorylated.?
2Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomacell linePS8123566222
[Reference]: Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia
3Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUS8321799006; 12015328
[Reference]: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites.
4Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUS9612015328
[Reference]: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites.
5Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomatumor tissueUS21023580588
[Reference]: While pAR210 was predominantly found in CR PC patients (P<0.0001), pAR210 positivity was observed in a subgroup of HN PC patients with a poor survival
6Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUS21322986532
[Reference]: Thus, AR phosphorylation by PIM1 at S213 impacts gene transcription and is highly prevalent in aggressive prostate cancer
7Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUS25812015328
[Reference]: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites.
8Serine PhosphorylationHormone naive prostate cancerPS30823945560
[Reference]: high pAR308 is significantly associated with a longer time to disease specific death (p = 0.011) and high pAR791 expression significantly associated with a longer time to disease recurrence (p = 0.018) in HNPC tumours and longer time to death from disease recurrence (p = 0.040) in CRPC tumours
9Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUS30812015328
[Reference]: Treatment of LNCaP cells with the synthetic androgen, R1881, elevates phosphorylation of serines 16, 81, 256, 308, 424, and 650. Ser-94 appears constitutively phosphorylated.?
10Serine PhosphorylationAndrogen insensitivity syndromeCS40522334658
[Reference]: Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.
11Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUS42612015328
[Reference]: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites.
12Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomatumor tissuePS51523321516
[Reference]: Phosphorylation of AR at serine 515 (pAR(S515)) and PSA at diagnosis were independently associated with decreased time to biochemical relapse
13Serine PhosphorylationBreast cancer/tumor/carcinomaUS51528415597
[Reference]: Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
14Tyrosine PhosphorylationProstate cancer/carcinoma/adenocarcinomaUY53517045208
[Reference]: Phosphorylated Src and AR higher in hormone-refractory prostate cancers than hormone-sensitive ones.
15Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomaPS57823132866
[Reference]: p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2)
16AcetylationProstate cancer/carcinoma/adenocarcinomaNK63017483368
[Reference]: A K630T substitution was identified in a prostate cancer patient before the onset of androgen ablation therapy
17Serine PhosphorylationProstate cancer/carcinoma/adenocarcinomacell lineDS79223945560
[Reference]: High expression correlates with increased patient survival time from disease recurrence

※ Disease Cross-ref Annotation

DatabaseAnnotation
Cancer Gene Census
prostate
CTD (Curated)
(count: 20)
(view all)
MESH:D000505 ; Alopecia
MESH:D013734 ; Androgen-Insensitivity Syndrome
MESH:D001254 ; Astrocytoma
MESH:D001321 ; Autistic Disorder
MESH:D001943 ; Breast Neoplasms
MESH:D018567 ; Breast Neoplasms, Male
DisGeNet (Curated)
(count: 90)
(view all)
C0001973; Alcoholic Intoxication, Chronic
C0002170; Alopecia
C0004114; Astrocytoma
C0004352; Autistic Disorder
C0004509; Azoospermia
C0010417; Cryptorchidism
HGMD
(count: 391)
(view all)
CX910583; Spino-bulbar muscular atrophy (Kennedy disease); Repeat variations
CE994034; Androgen insensitivity syndrome; Repeat variations
CE972908; Prostate cancer, increased risk, association; Repeat variations
CE972909; Prostate cancer, increased risk, association; Repeat variations
HD030005; Androgen insensitivity syndrome; Small deletions
CD920831; Androgen insensitivity syndrome; Small deletions
GWASdb
(count: 17)
(view all)
rs12396249; Vascular dementia; vascular dementia
rs12396249; Male-pattern baldness; alopecia
rs1204038; Male-pattern baldness; alopecia
rs2255702; Male-pattern baldness; alopecia
rs5918757; Male-pattern baldness; alopecia
rs5919393; Vascular dementia; vascular dementia

※ PTM Sites

PTM Modification Sites
Phosphorylation
(count: 36)
(view all)
119       QQPSQPQSALECHPE     dbPAF
16        RVYPRPPSKTYRGAF     dbPAF
206       AVSEGSSSGRAREAS     dbPAF
213       SGRAREASGAPTSSK     dbPAF
217       REASGAPTSSKDNYL     dbPAF
223       PTSSKDNYLGGTSTI     dbPAF
Acetylation
(count: 3)
631       GMTLGARKLKKLGNL     PLMD
633       TLGARKLKKLGNLKL     PLMD
634       LGARKLKKLGNLKLQ     PLMD
Ubiquitination
(count: 2)
846       LDRIIACKRKNPTSC     PLMD
848       RIIACKRKNPTSCSR     PLMD
Sumoylation
(count: 2)
388       PHPHARIKLENPLDY     PLMD
521       YPSPTCVKSEMGPWM     PLMD
Methylation
(count: 2)
631       GMTLGARKLKKLGNL     PLMD
633       TLGARKLKKLGNLKL     PLMD

※ Protein-Protein Interaction

NetworkInteraction
ABSource
B0ZBF6P10275HPRD
B7Z7D7P10275HPRD
E9PAV7P10275HPRD
E9PFC7P10275HPRD
E9PH57P10275HPRD
H7C2I1P10275HPRD
O14595P10275HPRD; MINT
O14672P10275IntAct
O14976P10275HPRD; IntAct
O15164P10275HPRD
O43294P10275HPRD; DIP
O60244P10275HPRD
O60341P10275DIP;HPRD
O75376P10275HPRD
O75925P10275HPRD
O75928P10275HPRD
O94906P10275HPRD
O95238P10275HPRD; DIP
O95251P10275HPRD; IntAct; MINT
O95425P10275HPRD
O96028P10275MINT
P00533P10275HPRD
P03372P10275HPRD
P04049P10275HPRD
P04150P10275HPRD
P04406P10275HPRD
P04637P10275MINT
P05412P10275HPRD; DIP
P05771P10275DIP
P06396P10275HPRD; DIP
P06400P10275HPRD
P06493P10275HPRD
P07288P10275IntAct
P07900P10275HPRD; DIP
P08047P10275HPRD
P09429P10275HPRD
P10275P10275HPRD; MINT
P10275P10606HPRD
P10275P11308IntAct
P10275P12235HPRD
P10275P12931HPRD
P10275P12956HPRD
P10275P13010HPRD
P10275P13056HPRD
P10275P13984HPRD
P10275P14735HPRD
P10275P14859HPRD
P10275P15336HPRD
P10275P19447MINT
P10275P19838HPRD
P10275P20151HPRD
P10275P20711HPRD; IntAct
P10275P21333HPRD; DIP
P10275P24385HPRD; DIP
P10275P24864HPRD
P10275P27797HPRD
P10275P28482HPRD
P10275P29466HPRD
P10275P30304HPRD
P10275P30305HPRD
P10275P31749HPRD
P10275P32780HPRD
P10275P35222HPRD; IntAct; MINT
P10275P35269HPRD; DIP; IntAct
P10275P35869HPRD
P10275P38398DIP
P10275P40189HPRD
P10275P40763HPRD
P10275P41252HPRD
P10275P42574HPRD
P10275P48552HPRD
P10275P49023HPRD
P10275P49116DIP;HPRD
P10275P49841HPRD
P10275P50613HPRD; DIP
P10275P50750HPRD
P10275P51398HPRD
P10275P51843HPRD
P10275P51946HPRD; DIP
P10275P55210HPRD
P10275P55317HPRD
P10275P56524IntAct
P10275P60484HPRD
P10275P60709IntAct
P10275P60763HPRD
P10275P62158HPRD
P10275P62826HPRD; DIP
P10275P63165HPRD; IntAct
P10275P63244HPRD
P10275P63279HPRD; DIP
P10275P78317HPRD
P10275P82094HPRD; DIP
P10275P84022HPRD
P10275Q00534HPRD
P10275Q00987HPRD; DIP; IntAct
P10275Q01196HPRD
P10275Q01860HPRD
P10275Q03135HPRD; DIP
P10275Q04206HPRD
P10275Q05066HPRD
P10275Q05086HPRD; DIP
P10275Q05823HPRD
P10275Q06830IntAct
P10275Q08117HPRD
P10275Q09472HPRD
P10275Q12756HPRD
P10275Q12778HPRD; IntAct
P10275Q12796HPRD
P10275Q13285HPRD
P10275Q13485HPRD
P10275Q13547HPRD
P10275Q13620HPRD
P10275Q13772DIP; IntAct
P10275Q14192HPRD; MINT
P10275Q14686IntAct
P10275Q14790HPRD; MINT
P10275Q15020HPRD
P10275Q15233HPRD
P10275Q15466HPRD
P10275Q15583HPRD
P10275Q15596HPRD; DIP; IntAct; MINT
P10275Q15648HPRD
P10275Q15650HPRD
P10275Q15652HPRD; IntAct
P10275Q15788HPRD; IntAct
P10275Q15797HPRD; MINT
P10275Q16543HPRD
P10275Q16665HPRD; IntAct
P10275Q16666MINT;HPRD
P10275Q4LE28HPRD
P10275Q58WW2HPRD
P10275Q5MNZ9HPRD
P10275Q5T802HPRD
P10275Q5THR3HPRD
P10275Q8IZL8HPRD
P10275Q8N2W9HPRD
P10275Q92624HPRD
P10275Q92793IntAct
P10275Q92831HPRD
P10275Q92993DIP; MINT;HPRD
P10275Q96L73HPRD
P10275Q96PM5HPRD
P10275Q96S59HPRD
P10275Q99497IntAct
P10275Q99638HPRD
P10275Q99816HPRD
P10275Q99933HPRD; DIP
P10275Q9BQE5HPRD
P10275Q9BQG0HPRD
P10275Q9H422HPRD
P10275Q9NPJ4HPRD
P10275Q9NQU5HPRD
P10275Q9NYW8HPRD
P10275Q9P2W1HPRD
P10275Q9UBK9HPRD
P10275Q9UBS8HPRD; DIP; IntAct
P10275Q9UER7HPRD; IntAct
P10275Q9ULJ6HPRD
P10275Q9UNE7HPRD
P10275Q9UQ80HPRD; IntAct
P10275Q9Y252IntAct
P10275Q9Y265DIP
P10275Q9Y2I1HPRD
P10275Q9Y3R0HPRD
P10275Q9Y4B4HPRD
P10275Q9Y618HPRD
P10275Q9Y6Q9HPRD
P10275Q9Y6X2HPRD